HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Insights and future directions of potential genetic therapy for Apert syndrome: A systematic review.

Abstract
Apert syndrome is a genetic disorder characterised by craniosynostosis and structural discrepancy of the craniofacial region as well as the hands and feet. This condition is closely linked with fibroblast growth factor receptor-2 (FGFR2) gene mutations. Gene therapies are progressively being tested in advanced clinical trials, leading to a rise of its potential clinical indications. In recent years, research has made great progress in the gene therapy of craniosynostosis syndromes and several studies have investigated its influences in preventing/diminishing the complications of Apert syndrome. This article reviewed and exhibited different techniques of gene therapy and their influences in Apert syndrome progression. A systematic search was executed using electronic bibliographic databases including PubMed, EMBASE, ScienceDirect, SciFinder and Web of Science for all studies of gene therapy for Apert syndrome. The primary outcomes measurements vary from protein to gene expressions. According to the findings of included studies, we conclude that the gene therapy using FGF in Apert syndrome was critical in the regulation of suture fusion and patency, occurred via alterations in cellular proliferation. The superior outcome could be brought by biological therapies targeting the FGF/FGFR signalling. More studies in molecular genetics in Apert syndrome are recommended. This study reviews the current literature and provides insights to future possibilities of genetic therapy as intervention in Apert syndrome.
AuthorsNisreen Mohammed Al-Namnam, Soher Nagi Jayash, Firdaus Hariri, Zainal Ariff Abdul Rahman, Mohammed Abdullah Alshawsh
JournalGene therapy (Gene Ther) Vol. 28 Issue 10-11 Pg. 620-633 (11 2021) ISSN: 1476-5462 [Electronic] England
PMID33619359 (Publication Type: Journal Article, Review, Systematic Review)
Copyright© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.
Topics
  • Acrocephalosyndactylia (genetics, metabolism, therapy)
  • Cell Proliferation
  • Genetic Therapy
  • Humans
  • Mutation
  • Signal Transduction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: